0000000000131954

AUTHOR

François Bailly

showing 6 related works from this author

Amiodarone Pneumonitis

1992

Amiodarone (Am) pneumonitis is currently a common and potentially severe adverse reaction, the accurate diagnosis of which remains difficult to establish. Objectives: To determine the contribution of bronchoalveolar lavage (BAL) in the diagnostic workup of patients suspected of having Am pneumonitis. Methods: Diagnosis of Am pneumonitis was established on the basis of (1) development of recent symptoms and pulmonary opacities while receiving the drug, (2) exclusion of other possible causes, and (3) improvement following cessation of Am and/or steroid therapy. (4) Confirmatory changes were obtained by histopathologic examination in eight cases. BAL was performed in each patient at the time o…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPathologymedicine.diagnostic_testbusiness.industryrespiratory systemCritical Care and Intensive Care Medicinemedicine.diseaseAmiodaroneGastroenterologyPneumoniaBronchoalveolar lavageFibrosisInternal medicineToxicitymedicineCardiology and Cardiovascular MedicinebusinessAdverse effectLiterature surveyPneumonitismedicine.drugChest
researchProduct

Phase III, Multicenter Open-Label Study to Investigate the Efficacy of Elbasvir and Grazoprevir Fixed-Dose Combination for Eight Weeks in Treatment-N…

2020

Background: Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accordingly, we evaluated the efficacy of eight weeks fixed dose combination of grazoprevir-elbasvir in treatment-naive patients, with non-severe fibrosis. Methods: HCV mono-infected and treatment naive patients with non-severe fibrosis (Fibroscan®<9·5kPa and Fibrotest®<0·59) were enrolled in a study which included 117 patients. Genotyping by sequencing identified five patients with non-1b genotype (two GT1a, one GT1h, one GT1e and one GT1l). Thus, we…

medicine.medical_specialtyElbasvirbusiness.industryFixed-dose combinationHepatitis Cmedicine.diseaseClinical investigatorGrazoprevirInformed consentInternal medicineGood clinical practicemedicinebusinessViral loadSSRN Electronic Journal
researchProduct

Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF…

2021

Diagnosis of B-cell chronic lymphocytic leukemia (B-CLL) is usually straightforward, involving clinical, immunophenotypic (Matutes score), and (immuno)genetic analyses (to refine patient prognosis for treatment). CLL cases with atypical presentation (e.g., Matutes ≤ 3) are also encountered, and for these diseases, biology and prognostic impact are less clear. Here we report the genomic characterization of a case of atypical B-CLL in a 70-yr-old male patient; B-CLL cells showed a Matutes score of 3, chromosomal translocation t(14;18)(q32;q21) (BCL2/IGH), mutated IGHV, deletion 17p, and mutations in BCL2, NOTCH1 (subclonal), and TP53 (subclonal). Quite strikingly, a novel PAX5 mutation that w…

MaleProto-Oncogene Proteins B-rafChronic lymphocytic leukemiaCell Cycle ProteinsBiologymedicine.disease_causeSomatic evolution in cancerTranslocation GeneticEpigenesis Genetichematological neoplasmClonal Evolutionimmune system diseaseshemic and lymphatic diseasesExome SequencingmedicineHumansEpigeneticsReceptor Notch1neoplasmsLoss functionExome sequencingAgedHomeodomain ProteinsMutationPAX5 Transcription FactorGeneral Medicinemedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-CellProto-Oncogene Proteins c-bcl-2MutationCancer researchPAX5Tumor Suppressor Protein p53IGHV@Rapid Cancer CommunicationTranscription FactorsCold Spring Harbor Molecular Case Studies
researchProduct

Clinical Features And Course Of Refractory Anemia With Ring Sideroblasts Associated With Marked Thrombocytosis

2012

Background Refractory anemia with ring sideroblasts associated with marked thrombocytosis was proposed as a provisional entity in the 2001 World Health Organization classification of myeloid neoplasms and also in the 2008 version, but its existence as a single entity is contested. We wish to define the clinical features of this rare myelodysplastic/myeloproliferative neoplasm and to compare its clinical outcome with that of refractory anemia with ring sideroblasts and essential thrombocythemia. Design and Methods We conducted a collaborative retrospective study across Europe. Our database included 200 patients diagnosed with refractory anemia with ring sideroblasts and marked thrombocytosis…

AdultBlood PlateletsMalemedicine.medical_specialtyAdolescentAnemiaAnèmiaRefractory anemia with ringed sideroblastsLower riskGastroenterologyRisk FactorsInternal medicinehemic and lymphatic diseasesmedicineHumansMyeloproliferative neoplasmSurvival analysisAgedRetrospective StudiesTumorsAged 80 and overThrombocytosisThrombocytosisPlatelet CountEssential thrombocythemiabusiness.industryAnemia RefractoryAnemiaHematologyJanus Kinase 2Middle Agedmedicine.diseaseSurvival AnalysisAnemia SideroblasticSurgeryEuropeRefractory anemia with ring sideroblastsMutationFemaleOriginal Articles and Brief ReportsbusinessThrombocythemia Essential
researchProduct

Calreticulin Mutations in Myeloproliferative Neoplasms: Comparison of Three Diagnostic Methods

2015

International audience; Calreticulin (CALR) mutations have recently been reported in 70-84% of JAK2V617F-negative myeloproliferative neoplasms (MPN), and this detection has become necessary to improve the diagnosis of MPN. In a large single-centre cohort of 298 patients suffering from Essential Thrombocythemia (ET), the JAK2V617F, CALR and MPL mutations were noted in 179 (60%), 56 (18.5%) and 13 (4.5%) respectively. For the detection of the CALR mutations, three methods were compared in parallel: high-resolution melting-curve analysis (HRM), product-sizing analysis and Sanger sequencing. The sensitivity for the HRM, product-sizing analysis and Sanger sequencing was 96.4%, 98.2% and 89.3% re…

AdultMaleSequence analysislcsh:MedicineBiologymedicine.disease_causeSensitivity and SpecificityDNA sequencingFrameshift mutationYoung Adult03 medical and health sciencessymbols.namesake0302 clinical medicineINDEL MutationmedicineHumanslcsh:ScienceFrameshift MutationAged030304 developmental biologyAged 80 and overSanger sequencingGenetics0303 health sciencesMutationMultidisciplinaryEssential thrombocythemialcsh:RMiddle Agedmedicine.disease3. Good health030220 oncology & carcinogenesisBone marrow neoplasmMutationbiology.proteinsymbolslcsh:QFemaleBone Marrow NeoplasmsCalreticulinSequence AnalysisCalreticulin[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyResearch ArticlePLOS ONE
researchProduct

Trends in Incidence and Survival of Myeloid Malignancies Since 1980, in the Côte D'or Department, Burgundy, France.

2009

Abstract Abstract 3122 Poster Board III-59 Objective The Registry of Haematological Malignancies (HM) has been established on January 1st, 1980 in the department of Côte d'Or (pop 500 000 inhabitants). It was the first specialized registry in haematology in the world. During the course of 25 years (1980-2004), 5026 cases of HM were recorded including 1553 Myeloid malignancies (MM) in which entities not initially considered as malignant were taken in account such as Myelodysplastic syndrome (MDS) and some Myeloproliferative neoplasms (MPN). This allow us to present trends in incidence and survival of myeloid malignancies by entities since 1980. Method MM diagnosed in the population between …

Pediatricsmedicine.medical_specialtyeducation.field_of_studyMyeloidHematologyRelative survivalbusiness.industryEssential thrombocythemiaIncidence (epidemiology)ImmunologyPopulationCell BiologyHematologymedicine.diseaseBiochemistrymedicine.anatomical_structureInternal medicinemedicineChromosome abnormalitybusinesseducationSex ratioBlood
researchProduct